1
|
Blough B, Namjoshi O. Small Molecule Neuropeptide S and Melanocortin 4 Receptor Ligands as Potential Treatments for Substance Use Disorders. Handb Exp Pharmacol 2019; 258:61-87. [PMID: 31628605 DOI: 10.1007/164_2019_313] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
There is a vital need for novel approaches and biological targets for drug discovery and development. Treatment strategies for substance use disorders (SUDs) to date have been mostly ineffective other than substitution-like therapeutics. Two such targets are the peptide G-protein-coupled receptors neuropeptide S (NPS) and melanocortin 4 (MC4). Preclinical evidence suggests that antagonists, inverse agonists, or negative allosteric modulators of these receptors might be novel therapeutics for SUDs. NPS is a relatively unexplored receptor with high potential for treating SUD. MC4 has a strong link to early-onset obesity, and emerging evidence suggests significant overlap between food-maintained and drug-maintained behaviors making MC4 an intriguing target for SUD. This chapter provides an overview of the literature in relation to the roles of NPS and MC4 in drug-seeking behaviors and then provides a medicinal chemistry-based survey of the small molecule ligands for each receptor.
Collapse
Affiliation(s)
- Bruce Blough
- Center for Drug Discovery, RTI International, Research Triangle Park, NC, USA.
| | - Ojas Namjoshi
- Center for Drug Discovery, RTI International, Research Triangle Park, NC, USA
| |
Collapse
|
2
|
Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC. Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem 2018; 61:7168-7188. [DOI: 10.1021/acs.jmedchem.8b00450] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Huy H. Nguyen
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Michelle B. Kim
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Robert J. Wilson
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Christopher J. Butch
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Katie M. Kuo
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Eric J. Miller
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Yesim A. Tahirovic
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Edgars Jecs
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Valarie M. Truax
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Tao Wang
- Research & Development, Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States
| | - Chi S. Sum
- Research & Development, Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States
| | - Mary E. Cvijic
- Research & Development, Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States
| | - Gretchen M. Schroeder
- Research & Development, Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States
| | - Lawrence J. Wilson
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Dennis C. Liotta
- Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States
| |
Collapse
|
3
|
Sun Q, Wang J, Li Y, Zhuang J, Zhang Q, Sun X, Sun D. Synthesis and evaluation of cytotoxic activities of artemisinin derivatives. Chem Biol Drug Des 2017; 90:1019-1028. [DOI: 10.1111/cbdd.13016] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Revised: 02/15/2017] [Accepted: 04/23/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Qian Sun
- Marine College; Shandong University at Weihai; Weihai China
| | - Jin Wang
- Marine College; Shandong University at Weihai; Weihai China
| | - Yao Li
- Marine College; Shandong University at Weihai; Weihai China
| | | | - Qian Zhang
- Marine College; Shandong University at Weihai; Weihai China
| | - Xiao Sun
- Marine College; Shandong University at Weihai; Weihai China
| | - Dequn Sun
- Marine College; Shandong University at Weihai; Weihai China
| |
Collapse
|
4
|
Huang LH, Xu HD, Yang ZY, Zheng YF, Liu HM. Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid-nucleosides analogues. Steroids 2014; 82:1-6. [PMID: 24378780 DOI: 10.1016/j.steroids.2013.12.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Revised: 12/04/2013] [Accepted: 12/13/2013] [Indexed: 11/17/2022]
Abstract
Novel C6-piperazine substituted purine nucleoside analogues (2-9) bearing a modified pyranose-like D ring of the 4-azasteroid moiety were efficiently synthesized through nucleophilic substitution at C6 position of the steroid-nucleoside precursors (1) with versatile piperazines. All newly-synthesized compounds were evaluated for their anticancer activity in vitro against Hela, PC-3 and MCF-7 cell lines. Among them, compounds 8b and 9b exhibited significant cytotoxicity on PC-3 cell lines.
Collapse
Affiliation(s)
- Li-Hua Huang
- College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou 450001, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, China
| | - Hong-De Xu
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, China
| | - Zhuo-Ya Yang
- College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou 450001, China
| | - Yong-Fei Zheng
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, China
| | - Hong-Min Liu
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, China.
| |
Collapse
|
5
|
Yang Y, Hruby VJ, Chen M, Crasto C, Cai M, Harmon CM. Novel binding motif of ACTH analogues at the melanocortin receptors. Biochemistry 2009; 48:9775-84. [PMID: 19743876 DOI: 10.1021/bi900634e] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The melanocortin receptor (MCR) subtype family is a member of the GPCR superfamily, and each of them has a different pharmacological profile with regard to the relative potency of the endogenous and synthetic melanocortin peptides. Alpha-MSH and ACTH are endogenous nonselective agonists for MC1R, MC3R, MC4R, and MC5R. In this study, we examined the role of Phe(7) in ACTH on human (h) MC1R, MC3R, and MC4R binding and signaling. Our results indicate that substitution of Phe(7) with d-Nal(2')(7) in ACTH1-24 yields a pharmacological profile different from that for substitution of Phe(7) with d-Nal(2')(7) in MSH in hMC1R, hMC3R, and hMC4R. N-d-Nal(2')(7)-ACTH1-24 is an agonist at hMC3R and hMC4R which did not change the peptide from an agonist to an antagonist at hMC3R and hMC4R. Further experiments indicate that N-d-Nal(2')(7)-ACTH1-17 is the minimal peptide required for hMC3R and hMC4R activation. Single-amino acid substitution studies of d-Nal(2')(7)-ACTH1-17 indicate that amino acid residues 15-17 in N-d-Nal(2')(7)-ACTH1-17 are crucial for hMC3R and hMC4R activation. Substitutions of these amino acid residues reduced or abolished agonist activity at hMC3R and hMC4R. Conformational studies revealed a new beta-turn (Arg(8)-Trp(9)-Gly(10)-Lys(11)) in N-d-Nal(2')(7)-ACTH1-17, compared to the beta-turn-like structure at NDP-alpha-MSH (His(6)-d-Phe(7)-Arg(8)-Trp(9)). Our results suggest that NDP-alpha-MSH and N-d-Nal(2')(7)-ACTH1-17 do not share the same binding site; the highly basic C-terminal fragment (Lys(15)-Lys(16)-Arg(17)) of N-d-Nal(2')(7)-ACTH1-17 induced a new beta-turn, and this shift contributed the selective agonist activity at hMC3R and hMC4R.
Collapse
Affiliation(s)
- Yingkui Yang
- Department of Surgery, University of Alabama, Birmingham, Alabama 35233, USA.
| | | | | | | | | | | |
Collapse
|
6
|
Yang Y, Cai M, Chen M, Qu H, McPherson D, Hruby V, Harmon CM. Key amino acid residues in the melanocortin-4 receptor for nonpeptide THIQ specific binding and signaling. REGULATORY PEPTIDES 2009; 155:46-54. [PMID: 19303903 PMCID: PMC3216638 DOI: 10.1016/j.regpep.2009.03.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/27/2008] [Revised: 03/06/2009] [Accepted: 03/07/2009] [Indexed: 11/20/2022]
Abstract
Melanocortin 4 receptor (MC4R) plays an important role in the regulation of food intake and glucose homeostasis. Synthetic nonpeptide compound N- (3R)-1 4-tetrahydroisoquinolinium-3-ylcarbonyl-(1R)-1-(4-chlorobenzyl)-2-4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl-2-oxoethylamine (THIQ) is a potent agonist at MC4R but not at hMC2R. In this study, we utilized two approaches (chimeric receptor and site-directed mutagenesis) to narrow down the key amino acid residues of MC4R responsible for THIQ binding and signaling. Cassette substitutions of the second, third, fourth, fifth, and sixth transmembrane regions (TMs) of the human MC4R (hMC4R) with the homologous regions of hMC2R were constructed. Our results indicate that the cassette substitutions of these TMs of the hMC4R with homologous regions of the hMC2R did not significantly alter THIQ binding affinity and potency except the substitution of the hMC4R TM3, suggesting that the conserved amino acid residues in these TMs of the hMC4R are main potential candidates for THIQ binding and signaling while non conserved residues in TM3 of MC4R may also be involved. Nineteen MC4R mutants were then created, including 13 conserved amino acid residues and 6 non-conserved amino acid residues. Our results indicate that seven conserved residue [E100 (TM2), D122 (TM3), D126 (TM3), F254 (TM6), W258 (TM6), F261 (TM6), H264 (TM6)] are important for THIQ binding and three non-conserved residues [N123 (TM3), I129 (TM3) and S131 (TM3)] are involved in THIQ selectivity. In conclusion, our results suggest that THIQ utilize both conserved and non-conserved amino acid residues for binding and signaling at hMC4R and non conserved residues may be responsible for MC4R selectivity.
Collapse
Affiliation(s)
- Yingkui Yang
- Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
| | | | | | | | | | | | | |
Collapse
|
7
|
Drugability of extracellular targets: discovery of small molecule drugs targeting allosteric, functional, and subunit-selective sites on GPCRs and ion channels. Neuropsychopharmacology 2009; 34:106-25. [PMID: 18800070 DOI: 10.1038/npp.2008.149] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Beginning with the discovery of the structure of deoxyribose nucleic acid in 1953, by James Watson and Francis Crick, the sequencing of the entire human genome some 50 years later, has begun to quantify the classes and types of proteins that may have relevance to human disease with the promise of rapidly identifying compounds that can modulate these proteins so as to have a beneficial and therapeutic outcome. This so called 'drugable space' involves a variety of membrane-bound proteins including the superfamily of G-protein-coupled receptors (GPCRs), ion channels, and transporters among others. The recent number of novel therapeutics targeting membrane-bound extracellular proteins that have reached the market in the past 20 years however pales in magnitude when compared, during the same timeframe, to the advancements made in the technologies available to aid in the discovery of these novel therapeutics. This review will consider select examples of extracellular drugable targets and focus on the GPCRs and ion channels highlighting the corticotropin releasing factor (CRF) type 1 and gamma-aminobutyric acid receptors, and the Ca(V)2.2 voltage-gated ion channel. These examples will elaborate current technological advancements in drug discovery and provide a prospective framework for future drug development.
Collapse
|
8
|
Structure-activity relationship studies on a series of piperazinebenzylalcohols and their ketone and amine analogs as melanocortin-4 receptor ligands. Bioorg Med Chem Lett 2008; 18:4817-22. [PMID: 18682322 DOI: 10.1016/j.bmcl.2008.07.076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2008] [Revised: 07/18/2008] [Accepted: 07/22/2008] [Indexed: 11/23/2022]
Abstract
A series of piperazinebenzylalcohols were prepared and studied to compare with their ketone and amine analogs as MC4R antagonists. Several benzylalcohols such as 14a and 14g displayed low nanomolar binding affinities (K(i)<10 nM), and high selectivities over other melanocortin receptor subtypes.
Collapse
|
9
|
Tran JA, Tucci FC, Arellano M, Jiang W, Chen CW, Marinkovic D, Fleck BA, Wen J, Foster AC, Chen C. Design and synthesis of 3-arylpyrrolidine-2-carboxamide derivatives as melanocortin-4 receptor ligands. Bioorg Med Chem Lett 2008; 18:1931-8. [PMID: 18294847 DOI: 10.1016/j.bmcl.2008.01.125] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2007] [Revised: 01/30/2008] [Accepted: 01/31/2008] [Indexed: 11/26/2022]
Abstract
Based on 3-phenylpropionamides, a series of 3-arylpyrrolidine-2-carboxamide derivatives was designed and synthesized to study the effect of cyclizations as melanocortin-4 receptor ligands. It was found that the 2R,3R-pyrrolidine isomer possessed the most potent affinity among the four stereoisomers.
Collapse
Affiliation(s)
- Joe A Tran
- Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Mayorov AV, Cai M, Palmer ES, Dedek MM, Cain JP, Van Scoy AR, Tan B, Vagner J, Trivedi D, Hruby VJ. Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 receptor. J Med Chem 2008; 51:187-95. [PMID: 18088090 PMCID: PMC2587288 DOI: 10.1021/jm070461w] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A variety of dicarboxylic acid linkers introduced between the alpha-amino group of Pro(6) and the -amino group of Lys(10) of the cyclic lactam alpha-melanocyte-stimulating hormone (alpha-MSH)-derived Pro(6)-D-Phe(7)/D-Nal(2')(7)-Arg(8)-Trp(9)-Lys(10)-NH2 pentapeptide template lead to nanomolar range and selective hMC3R agonists and antagonists. Replacement of the Pro(6) residue and the dicarboxylic acid linker with 2,3-pyrazine-dicarboxylic acid furnished a highly selective nanomolar range hMC3R partial agonist (analogue 12, c[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2, EC50 = 27 nM, 70% max cAMP) and an hMC3R antagonist (analogue 13, c[CO-2,3-pyrazine-CO-D-Nal(2')-Arg-Trp-Lys]-NH2, IC50 = 23 nM). Modeling experiments suggest that 2,3-pyrazinedicarboxylic acid stabilizes a beta-turn-like structure with the D-Phe/D-Nal(2') residues, which explains the high potency of the corresponding peptides. Placement of a Nle residue in position 6 produced a hMC3R/hMC5R antagonist (analogue 15, c[CO-(CH 2)2-CO-Nle-D-Nal(2')-Arg-Trp-Lys]-NH2, IC50 = 12 and 17 nM, respectively), similarly to the previously described cyclic gamma-melanocyte-stimulating hormone (gamma-MSH)-derived hMC3R/hMC5R antagonists. These newly developed melanotropins will serve as critical biochemical tools for elucidating the full spectrum of functions performed by the physiologically important melanocortin-3 receptor.
Collapse
MESH Headings
- Binding, Competitive
- Cell Line
- Cyclic AMP/biosynthesis
- Humans
- Lactams/chemical synthesis
- Lactams/pharmacology
- Models, Molecular
- Peptides, Cyclic/chemical synthesis
- Peptides, Cyclic/chemistry
- Peptides, Cyclic/pharmacology
- Radioligand Assay
- Receptor, Melanocortin, Type 3/agonists
- Receptor, Melanocortin, Type 3/antagonists & inhibitors
- Receptor, Melanocortin, Type 3/chemistry
- Structure-Activity Relationship
- alpha-MSH/analogs & derivatives
- alpha-MSH/chemical synthesis
- alpha-MSH/pharmacology
Collapse
Affiliation(s)
| | - Minying Cai
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| | - Erin S. Palmer
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| | - Matthew M. Dedek
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| | - James P. Cain
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| | - April R. Van Scoy
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| | - Bahar Tan
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| | - Josef Vagner
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| | - Dev Trivedi
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| | - Victor J. Hruby
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721
| |
Collapse
|
11
|
Tran JA, Tucci FC, Jiang W, Marinkovic D, Chen CW, Arellano M, Markison S, Fleck BA, Wen J, White NS, Pontillo J, Saunders J, Marks D, Hoare SR, Madan A, Foster AC, Chen C. Pyrrolidinones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activity. Bioorg Med Chem 2007; 15:5166-76. [PMID: 17544282 DOI: 10.1016/j.bmc.2007.05.026] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2006] [Revised: 05/03/2007] [Accepted: 05/10/2007] [Indexed: 11/24/2022]
Abstract
A series of pyrrolidinones derived from phenylalanines were synthesized as potent antagonists of the human melanocortin-4 receptor. These compounds showed high potencies and selectivities, and several of them had good oral bioavailabilities. In addition, 12e demonstrated in vivo efficacy in a murine cachexia model.
Collapse
Affiliation(s)
- Joe A Tran
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors. Chem Rev 2007; 107:2960-3041. [PMID: 17622179 DOI: 10.1021/cr050984g] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jade S Blakeney
- Centre for Drug Design and Development, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | |
Collapse
|
13
|
Nozawa D, Okubo T, Ishii T, Kakinuma H, Chaki S, Okuyama S, Nakazato A. Structure–activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor. Bioorg Med Chem 2007; 15:1989-2005. [PMID: 17234422 DOI: 10.1016/j.bmc.2006.12.039] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2006] [Revised: 12/22/2006] [Accepted: 12/23/2006] [Indexed: 10/23/2022]
Abstract
During the investigation of antagonists for the MC4 receptor, we found that 10ab having a naphthyl group showed almost the same binding affinity for the MC4 receptor as that of the lead compound 1 with a benzoyl group. We also developed a new type of compounds, namely, bis-piperazines, and found that the bis-piperazines 10 exhibited a high affinity for the MC4 receptor. In particular, (-)-10bg exhibited the highest affinity for the MC4 receptor with an IC50 value of 8.13nM. In this paper, we present the design, synthesis, and structure-activity relationships of the novel bis-piperazines as MC4 receptor antagonists.
Collapse
Affiliation(s)
- Dai Nozawa
- Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan.
| | | | | | | | | | | | | |
Collapse
|
14
|
Nozawa D, Okubo T, Ishii T, Takamori K, Chaki S, Okuyama S, Nakazato A. Novel piperazines: Potent melanocortin-4 receptor antagonists with anxiolytic-like activity. Bioorg Med Chem 2007; 15:2375-85. [PMID: 17267226 DOI: 10.1016/j.bmc.2007.01.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2006] [Revised: 01/12/2007] [Accepted: 01/13/2007] [Indexed: 11/22/2022]
Abstract
In the present study, we found that a novel piperazine compound, 11a, showed a moderate affinity (IC(50)=333nM) for the MC4 receptor. We developed the new type of piperazine compounds and found that mono-piperazine 11b exhibited a high-affinity (IC(50)=40.3nM) for the MC4 receptor. We also found that a series of biphenyl analogues exhibited a high-affinity for the receptor, and in particular, compound 11j exhibited the highest affinity for the MC4 receptor with an IC(50) value of 14.5nM. Furthermore, some of these compounds, when administered orally, significantly reversed the stress-induced anxiety-like behavior in rats. In this paper, we report the synthesis, structure-activity relationships, and oral activity of the novel mono-piperazines as MC4 receptor antagonists.
Collapse
Affiliation(s)
- Dai Nozawa
- Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan.
| | | | | | | | | | | | | |
Collapse
|
15
|
Chen C. Recent progress toward nonpeptide ligands for the melanocortin-4 receptor. PROGRESS IN MEDICINAL CHEMISTRY 2007; 45:111-67. [PMID: 17280903 DOI: 10.1016/s0079-6468(06)45503-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Affiliation(s)
- Chen Chen
- Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., 12700 El Camino Real, San Diego, CA 92130, USA
| |
Collapse
|
16
|
Newton C. The Role of Small- or Medium-Sized Enterprises in Drug Discovery. COMPREHENSIVE MEDICINAL CHEMISTRY II 2007. [PMCID: PMC7152157 DOI: 10.1016/b0-08-045044-x/00016-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The past 10 years has seen the rise of large numbers of small- and medium-size enterprises (SMEs) engaging in some or many of the aspects of drug research. Few of these companies have been able to take candidate drugs to market due to development costs not being met by funding opportunities, but those companies that have been able to challenge traditional big pharma in the marketplace. Most SMEs have instead supplied traditional pharma with pipeline candidate drugs, either by licensing them or by the large companies actually acquiring the whole of the SME which owns the intellectual property. Many other companies engage in providing traditional big pharma or other SMEs with technologies and services. Hundreds of such companies have arisen, many clustered around centres of academic excellence on the coasts of the USA, or in certain regions in Europe and Asia – such clustering of scientific prowess has changed the location of where even big pharma tends to perform its research. By 2006, a large proportion (but generally less than 50%) of new drugs could be track to an origin in an SME, trends indicate that the proportion will rise even though the common prediction that large pharma will abandon internal research in favour of in-licensing from SMEs remains far from reality.
Collapse
|
17
|
Nozawa D, Okubo T, Ishii T, Chaki S, Okuyama S, Nakazato A. Synthesis of Diphenylmethyl Analogues and Their Affinity for the Melanocortin-4 Receptor and the Serotonin Transporter. Chem Pharm Bull (Tokyo) 2007; 55:1044-50. [PMID: 17603198 DOI: 10.1248/cpb.55.1044] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
While examining antagonists of the melanocortin-4 receptor (MC4 receptor), we found that compound 12b, containing a diphenylmethyl moiety, had a relatively high affinity for the MC4 receptor. When diphenylmethyl analogues were further examined, compounds 12c and 18 were also found to exhibit a high affinity for the MC4 receptor (IC(50)=46.7 nM and 33.2 nM, respectively). Furthermore, compound 12c was also found to show a high affinity for the serotonin transporter (IC(50)=10.7 nM). Here, we describe the synthesis and biological evaluation of various diphenylmethyl analogues in relation to their actions on the MC4 receptor and the serotonin transporter.
Collapse
Affiliation(s)
- Dai Nozawa
- Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd, Saitama, Japan.
| | | | | | | | | | | |
Collapse
|
18
|
Martinelli A, Tuccinardi T. An overview of recent developments in GPCR modelling: methods and validation. Expert Opin Drug Discov 2006; 1:459-76. [DOI: 10.1517/17460441.1.5.459] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
19
|
Jiang W, Tucci FC, Chen CW, Arellano M, Tran JA, White NS, Marinkovic D, Pontillo J, Fleck BA, Wen J, Saunders J, Madan A, Foster AC, Chen C. Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2006; 16:4674-8. [PMID: 16777413 DOI: 10.1016/j.bmcl.2006.05.088] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2006] [Revised: 05/23/2006] [Accepted: 05/30/2006] [Indexed: 11/20/2022]
Abstract
A series of 3-arylpropionylpiperazines were synthesized as antagonists of the melanocortin-4 receptor. Their potency was found to be increased by replacing the alpha-methyl substituent of the initial lead 11 with a larger s-Bu or i-Bu group. Further potency enhancement was observed when a glycine or beta-alanine was incorporated onto the benzylamine. Some compounds demonstrated good potency, moderate selectivity, and oral bioavailability.
Collapse
Affiliation(s)
- Wanlong Jiang
- Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Chen CW, Tran JA, Jiang W, Tucci FC, Arellano M, Wen J, Fleck BA, Marinkovic D, White NS, Pontillo J, Saunders J, Madan A, Foster AC, Chen C. Propionylpiperazines as human melanocortin-4 receptor ligands. Bioorg Med Chem Lett 2006; 16:4800-3. [PMID: 16824757 DOI: 10.1016/j.bmcl.2006.06.075] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2006] [Revised: 06/21/2006] [Accepted: 06/22/2006] [Indexed: 11/22/2022]
Abstract
A series of alpha-benzylpropionylpiperazines were synthesized and tested as antagonists of the melanocortin-4 receptor. In addition to its high potency and selectivity, R-11a had desirable pharmacokinetic properties including high brain penetration in mice.
Collapse
Affiliation(s)
- Caroline W Chen
- Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Tian X, Field TB, Switzer AG, Mazur AW, Ebetino FH, Wos JA, Berberich SM, Jayasinghe LR, Obringer CM, Dowty ME, Pinney BB, Farmer JA, Crossdoersen D, Sheldon RJ. Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach. J Med Chem 2006; 49:4745-61. [PMID: 16854081 DOI: 10.1021/jm060384p] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The design, synthesis, and structure-activity relationships (SAR) of a series of novel proline and pyrrolidine based melanocortin receptor (MCR) agonists are described. To validate a conformationally constrained Arg-Nal dipeptide analogue strategy, we first synthesized and evaluated a test set of cis-(2R,4R)-proline analogues (21a-g). All of these compounds showed significant binding and agonist potency at the hMC1R, hMC3R, and hMC4R. Potent cis-(2S,4R)-pyrrolidine based MCR agonists (35a-g) were subsequently developed by means of this design approach. A SAR study directed toward probing the effect of the two chiral centers in the pyrrolidine ring on biological activity revealed the importance of the (S) absolute configuration at the 2-position for binding affinity, agonist potency, and receptor selectivity. Among the four sets of the pyrrolidine diastereomers investigated, analogues with the (2S,4R) configuration were the most potent agonists across the three receptors, followed by those possessing the (2S,4S) configuration.
Collapse
Affiliation(s)
- Xinrong Tian
- Procter & Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, Ohio 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Tran JA, Pontillo J, Fleck BA, Marinkovic D, Arellano M, Tucci FC, Lanier M, Saunders J, Jiang W, Chen CW, Foster AC, Chen C. Design, synthesis, and SAR studies on a series of 2-pyridinylpiperazines as potent antagonists of the melanocortin-4 receptor. Bioorg Med Chem Lett 2006; 16:3693-6. [PMID: 16697187 DOI: 10.1016/j.bmcl.2006.04.069] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2006] [Revised: 04/21/2006] [Accepted: 04/21/2006] [Indexed: 11/16/2022]
Abstract
A series of 2-pyridinylpiperazines derived from beta-Ala-(2,4-Cl)Phe dipeptide was synthesized for the study of their SARs and possible interactions with the MC4 receptor. Compounds such as 11k (Ki=6.5 nM) possessed high potency.
Collapse
Affiliation(s)
- Joe A Tran
- Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Vos TJ, Balani S, Blackburn C, Chau RW, Danca MD, Drabic SV, Farrer CA, Patane MA, Stroud SG, Yowe DL, Claiborne CF. Identification and structure–activity relationships of a new series of Melanocortin-4 receptor antagonists. Bioorg Med Chem Lett 2006; 16:2302-5. [PMID: 16458508 DOI: 10.1016/j.bmcl.2006.01.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2005] [Accepted: 01/06/2006] [Indexed: 11/25/2022]
Abstract
The identification and optimization of a series of acylguanidine-based melanocortin-4 receptor antagonists is discussed.
Collapse
Affiliation(s)
- Tricia J Vos
- Millennium Pharmaceuticals, Inc. 40 Landsdowne St. Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Pontillo J, Tran JA, White NS, Arellano M, Fleck BA, Marinkovic D, Tucci FC, Saunders J, Foster AC, Chen C. Structure–activity relationship studies on a series of cyclohexylpiperazines bearing a phanylacetamide as ligands of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2005; 15:5237-40. [PMID: 16183282 DOI: 10.1016/j.bmcl.2005.08.061] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2005] [Revised: 08/17/2005] [Accepted: 08/17/2005] [Indexed: 10/25/2022]
Abstract
Synthesis and structure-activity relationship studies of a series of cyclohexylpiperazines bearing an amide side chain as ligands of the MC4 receptor are discussed. Compounds such as 11i from this series are potent agonists (EC(50)=33nM, IA=96%).
Collapse
Affiliation(s)
- Joseph Pontillo
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc., 12790 El Camino Real, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Shi Q, Ornstein PL, Briner K, Richardson TI, Arnold MB, Backer RT, Buckmaster JL, Canada EJ, Doecke CW, Hertel LW, Honigschmidt N, Hsiung HM, Husain S, Kuklish SL, Martinelli MJ, Mullaney JT, O'Brien TP, Reinhard MR, Rothhaar R, Shah J, Wu Z, Xie C, Zgombick JM, Fisher MJ. Synthesis and structure-activity relationships of novel dipeptides and reduced dipeptides as ligands for melanocortin subtype-4 receptor. Bioorg Med Chem Lett 2005; 16:2341-6. [PMID: 16297618 DOI: 10.1016/j.bmcl.2005.10.103] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2005] [Revised: 10/28/2005] [Accepted: 10/28/2005] [Indexed: 11/29/2022]
Abstract
A series of benzylic piperazines (e.g., 4 and 5) attached to an 'address element', the dipeptide H-D-Tic-D-p-Cl-Phe-OH, 3 has been identified as ligands for the melanocortin subtype-4 receptor (MC4R). We describe herein the structure-activity relationship (SAR) studies on the N-terminal residue of the 'address element'. Several novel dipeptides and reduced dipeptides with high MC4R binding affinities and selectivity emerged from this SAR study.
Collapse
Affiliation(s)
- Qing Shi
- Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Tucci FC, White NS, Markison S, Joppa M, Tran JA, Fleck BA, Madan A, Dyck BP, Parker J, Pontillo J, Arellano LM, Marinkovic D, Jiang W, Chen CW, Gogas KR, Goodfellow VS, Saunders J, Foster AC, Chen C. Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines. Bioorg Med Chem Lett 2005; 15:4389-95. [PMID: 16098742 DOI: 10.1016/j.bmcl.2005.06.071] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2005] [Revised: 06/08/2005] [Accepted: 06/09/2005] [Indexed: 10/25/2022]
Abstract
The melanocortin-4 receptor (MC4R) plays an important role in the regulation of energy homeostasis. Recent studies have shown that blockade of the MC4R reverses tumor-induced weight loss in mice. Herein, we describe the synthesis and identification of potent and selective non-peptide antagonists of the human MC4R from a series of 2-ethoxycarbonylcyclohexyl-piperazines. Compound 12i was found to possess low nanomolar affinity for the MC4R, and exhibit oral bioavailability in rats. More importantly, when administered orally to mice (10 mg/kg), it led to statistically significant increases in food intake over a 24-h period.
Collapse
Affiliation(s)
- Fabio C Tucci
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc., 12790 El Camino Real, San Diego, CA 92130, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Pontillo J, Marinkovic D, Tran JA, Arellano M, Fleck BA, Wen J, Tucci FC, Nelson J, Saunders J, Foster AC, Chen C. Optimization of piperazinebenzylamines with a N-(1-methoxy-2-propyl) side chain as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2005; 15:4615-8. [PMID: 16105734 DOI: 10.1016/j.bmcl.2005.06.058] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2005] [Accepted: 06/10/2005] [Indexed: 11/26/2022]
Abstract
Piperazinebenzylamines bearing a small N-(1-methoxy-2-propyl) side chain were found to be potent and selective antagonists of the human melanocortin-4 (MC4) receptor. Compound 7b, having K(i) values of 6.9 and 2800 nM at the human MC4 and MC3 receptors, respectively, has moderate oral bioavailability in mice, which is improved relative to the arylethyl analogues.
Collapse
Affiliation(s)
- Joseph Pontillo
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc., 12790 El Camino Real, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Tran JA, Pontillo J, Arellano M, Fleck BA, Tucci FC, Marinkovic D, Chen CW, Saunders J, Foster AC, Chen C. Structure–activity relationship of a series of cyclohexylpiperidines bearing an amide side chain as antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2005; 15:3434-8. [PMID: 15950470 DOI: 10.1016/j.bmcl.2005.05.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2005] [Revised: 04/29/2005] [Accepted: 05/03/2005] [Indexed: 11/16/2022]
Abstract
A series of cyclohexylpiperazines was synthesized as potent and selective antagonists of the human MC4 receptor. Compound 14t displayed binding affinity (Ki) of 4.2 and 1100 nM at MC4R and MC3R, respectively.
Collapse
Affiliation(s)
- Joseph A Tran
- Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Pontillo J, Tran JA, Markison S, Joppa M, Fleck BA, Marinkovic D, Arellano M, Tucci FC, Lanier M, Nelson J, Saunders J, Hoare SRJ, Foster AC, Chen C. A potent and selective nonpeptide antagonist of the melanocortin-4 receptor induces food intake in satiated mice. Bioorg Med Chem Lett 2005; 15:2541-6. [PMID: 15863313 DOI: 10.1016/j.bmcl.2005.03.053] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2005] [Revised: 03/10/2005] [Accepted: 03/15/2005] [Indexed: 10/25/2022]
Abstract
Optimization on a series of piperazinebenzylamines resulted in analogues with low nanomolar binding at the human MC4 receptor but weak affinity (Ki > 500 nM) at the MC3 receptor. Compound 14c was identified to be a potent MC4R antagonist (Ki = 3.2 nM) with a selectivity of 240-fold over MC3R. It proved to be an insurmountable antagonist in a cAMP assay. Compound 14c potently stimulated food intake in satiated mice when given by intracerebroventricular administration.
Collapse
Affiliation(s)
- Joseph Pontillo
- Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|